{"id":992012,"date":"2026-08-07T00:00:33","date_gmt":"2026-08-07T04:00:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/"},"modified":"2026-08-07T00:00:33","modified_gmt":"2026-08-07T04:00:33","slug":"spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/","title":{"rendered":"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Aug. 6, 2026<\/span> \/PRNewswire\/ —<\/p>\n

\n

\n \"Rosen\n <\/p>\n<\/p><\/div>\n

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of\u00a0ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026.<\/p>\n

So what: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

What to do next: To join the ARS Pharmaceuticals class action, go to https:\/\/rosenlegal.com\/cases\/ars-pharmaceuticals-inc\/join<\/a>\u00a0or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com<\/a>\u00a0for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.\u00a0Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Details of the case: According to the lawsuit, defendants provided investors with material information concerning ARS Pharmaceuticals’ expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants’ statements included, among other things, confidence that this coverage would begin on July 1, 2026, and be in place for the summer and back-to-school allergy seasons.<\/p>\n

According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and\/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. This caused shareholders to purchase ARS Pharmaceuticals securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.\u00a0<\/p>\n

To join the ARS Pharmaceuticals class action, go to https:\/\/rosenlegal.com\/cases\/ars-pharmaceuticals-inc\/join<\/a>\u00a0or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com<\/a>\u00a0for information on the class action.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a>\u00a0or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0Laurence Rosen, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0Phillip Kim, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0New York, NY 10016
\u00a0\u00a0\u00a0\u00a0\u00a0Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0case@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0www.rosenlegal.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit-302845482.html<\/a><\/p>\n

SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Aug. 6, 2026 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of\u00a0ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. So what: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ARS Pharmaceuticals class action, go to … <\/p>\n

Continue reading “SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992012","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Aug. 6, 2026 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of\u00a0ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. So what: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ARS Pharmaceuticals class action, go to … Continue reading "SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T04:00:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1118010\/Rosen-Law-Firm-Logo.jpg?id=OA2834105\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit\",\"datePublished\":\"2026-08-07T04:00:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/\"},\"wordCount\":655,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1118010\\\/Rosen-Law-Firm-Logo.jpg?id=OA2834105\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/\",\"name\":\"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1118010\\\/Rosen-Law-Firm-Logo.jpg?id=OA2834105\",\"datePublished\":\"2026-08-07T04:00:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1118010\\\/Rosen-Law-Firm-Logo.jpg?id=OA2834105\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1118010\\\/Rosen-Law-Firm-Logo.jpg?id=OA2834105\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire NEW YORK, Aug. 6, 2026 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of\u00a0ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. So what: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ARS Pharmaceuticals class action, go to … Continue reading \"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-07T04:00:33+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1118010\/Rosen-Law-Firm-Logo.jpg?id=OA2834105","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit","datePublished":"2026-08-07T04:00:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/"},"wordCount":655,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1118010\/Rosen-Law-Firm-Logo.jpg?id=OA2834105","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/","name":"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1118010\/Rosen-Law-Firm-Logo.jpg?id=OA2834105","datePublished":"2026-08-07T04:00:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1118010\/Rosen-Law-Firm-Logo.jpg?id=OA2834105","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1118010\/Rosen-Law-Firm-Logo.jpg?id=OA2834105"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992012"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992012\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}